MPO and inflammatory bowel disease: Apigenin decreased myeloperoxidase (MPO), inflammatory cytokine and COX-2 levels and downregulated NF-κB and STAT3, thereby inhibiting inflammation and inflammation-induced carcinogenesis in an inflammatory bowel disease and colitis-associated cancer model [164].